Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METADATE ER vs ADDERALL 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methylphenidate is a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft. It also acts as a weak agonist at serotonin receptors.
Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy (off-label)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Initial: 10-20 mg orally once daily in the morning. May increase by 10-20 mg at weekly intervals. Maximum: 60 mg/day.
10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.
Terminal elimination half-life: 3-6 hours (mean 4.5 hours) for methylphenidate; clinical context: requires multiple daily dosing or extended-release formulation.
Terminal elimination half-life: dextroamphetamine 9-11 hours, levoamphetamine 11-14 hours (Adderall is a mixed salt). In adults, mean half-life ~10 hours; in children, slightly shorter (6-8 hours). Clinical context: steady-state reached in 2-3 days; dosing interval typically 4-6 hours for immediate-release.
Primarily hepatic via carboxylesterase CES1A1 to inactive metabolite ritalinic acid. Minor pathways include oxidative metabolism via CYP2D6. The drug undergoes extensive first-pass metabolism.
Amphetamine is metabolized primarily in the liver via cytochrome P450 enzymes, including CYP2D6, and undergoes deamination and oxidation to form inactive metabolites including 4-hydroxyamphetamine and norephedrine.
Renal (80% as metabolites, <1% unchanged); fecal (10-20%) via biliary elimination.
Renal: 70-80% (30-40% as unchanged amphetamine; remainder as deaminated and hydroxylated metabolites). Fecal: minimal (<5%). Biliary: negligible. Urinary p H affects excretion: acidic urine increases elimination, alkaline urine decreases.
10-33% (primarily albumin).
Amphetamine: 15-40% bound to plasma proteins (primarily albumin). Binding is not extensive, thus significant free fraction available for distribution.
Vd: 2-4 L/kg; indicates extensive tissue distribution and penetration into the central nervous system.
Apparent Vd: 3.0-4.0 L/kg (for total amphetamine). High Vd indicates extensive tissue distribution, including brain. Clinical meaning: loading dose may be needed for rapid effect; distribution half-life ~1 hour.
Oral: 30% (due to first-pass metabolism); Metadate ER: similar to immediate-release with extended dissolution profile.
Oral immediate-release: 100% (well-absorbed; first-pass metabolism minimal). Food delays absorption but does not affect extent. Extended-release: bioavailability similar to immediate-release with modified release profile.
No specific guidelines; use with caution in severe renal impairment (e GFR <30 m L/min/1.73m²) and consider dose reduction based on tolerability.
e GFR 15-29 m L/min: reduce dose by 50% and monitor for toxicity; e GFR <15 m L/min or dialysis: avoid use due to risk of accumulation; consider alternative therapy.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to decreased clearance and increased risk of toxicity.
Age ≥6 years: Initial 10-20 mg orally once daily; increase by 10 mg weekly. Maximum: 60 mg/day or 2 mg/kg/day, whichever is less.
Children 3-5 years: 2.5 mg orally once daily; may increase by 2.5 mg weekly; usual range 2.5-20 mg/day divided 1-2 times. Children 6 years and older: initial 5 mg once daily; may increase by 5 mg weekly; usual range 5-40 mg/day divided 1-3 times; maximum 40 mg/day.
Initiate at lower doses (e.g., 10 mg once daily) with cautious titration due to increased sensitivity and higher risk of adverse effects such as hypertension, agitation, and insomnia.
Initiate at 2.5-5 mg orally once daily; titrate slowly in increments of 2.5-5 mg weekly; monitor for cardiovascular effects, insomnia, and weight loss; maximum 40 mg/day.
METADATE ER has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events. Physicians should assess the risk of abuse before prescribing and monitor for signs of abuse during therapy.
Potential for abuse and dependence. Amphetamines have a high potential for abuse, which may lead to dependence and serious cardiovascular adverse events. Misuse may cause sudden death and serious cardiovascular events.
Serious cardiovascular events including sudden death in patients with structural cardiac abnormalities or other serious heart problems,Increased blood pressure and heart rate,Psychiatric adverse reactions including exacerbation of pre-existing psychosis, mania, or aggression,Seizures in patients with history of seizure disorders,Long-term suppression of growth in children,Potential for peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome when used with serotonergic drugs,Hematologic effects such as leukopenia and thrombocytopenia
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase; caution in hypertension and other cardiovascular conditions.,Psychiatric adverse events including exacerbation of psychosis, mania, and aggression.,Long-term suppression of growth in pediatric patients.,Peripheral vasculopathy including Raynaud's phenomenon.,Seizures: may lower seizure threshold.,Serotonin syndrome risk when co-administered with serotonergic drugs.
Hypersensitivity to methylphenidate or any component of the formulation,Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy,Glaucoma,Hyperthyroidism or thyrotoxicosis,Tics or family history of Tourette's syndrome,Severe hypertension or other cardiovascular conditions,History of drug abuse or dependence
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity or idiosyncrasy to sympathomimetic amines,Glaucoma,Agitated states,History of drug abuse,During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may occur)
Take with or without food. High-fat meals may delay the rate of absorption but not the extent. Avoid excessive caffeine intake as it may increase side effects like nervousness and palpitations. Alcohol should be avoided due to risk of altered release and increased adverse effects.
High-fat meals can delay absorption; avoid acidic foods (e.g., citrus, cola) within 1 hour of dosing as they decrease absorption. Avoid caffeine; may increase stimulant effects.
First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (including irritability, dysphoria, and feeding difficulties).
Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimesters: risk of fetal growth restriction, preterm delivery, and neonatal withdrawal symptoms (irritability, poor feeding).
Methylphenidate is excreted into breast milk in low concentrations (M/P ratio approximately 2.5). Short-term use is considered compatible with breastfeeding; however, observe infant for agitation, insomnia, and reduced weight gain. Avoid long-acting formulations due to higher milk concentrations.
Excreted into breast milk; relative infant dose estimated at 2-4% of maternal weight-adjusted dose. M/P ratio not well established. Manufacturer recommends caution; potential for infant agitation, insomnia, and growth suppression.
Increased clearance and volume of distribution during pregnancy may require dose adjustments. Plasma levels decrease by approximately 50% in the third trimester; consider increasing dose or switching to immediate-release formulation with more frequent dosing. Postpartum, monitor for toxicity as clearance returns to prepregnancy levels.
Increased plasma volume and enhanced hepatic metabolism may reduce amphetamine levels; dose adjustments should be individualized based on clinical response, but controlled studies lacking. Avoid abrupt discontinuation due to risk of withdrawal symptoms in mother and neonate.
METADATE ER is an extended-release formulation of methylphenidate. Avoid crushing or chewing capsules to prevent rapid release and potential toxicity. Monitor for blood pressure and heart rate changes, especially in patients with pre-existing cardiovascular conditions. Use with caution in patients with a history of seizures or drug dependence. Discontinue if signs of psychosis or severe depression occur.
Adderall 10 mg contains immediate-release amphetamine salts. Onset of action is 30-60 minutes, duration 4-6 hours. Monitor for appetite suppression, insomnia, and cardiovascular effects. Avoid in patients with structural cardiac abnormalities or history of substance abuse. Use with caution in hypertension or hyperthyroidism. Drug holidays may reduce tolerance.
Take exactly as prescribed; do not crush or chew capsules.,Swallow whole with or without food, usually in the morning.,Report any chest pain, shortness of breath, or fainting immediately.,Avoid alcohol while taking this medication.,Store at room temperature away from moisture and heat.,Do not suddenly stop taking without consulting your doctor.,May impair ability to drive or operate machinery until effects are known.
Take exactly as prescribed; do not crush or chew tablets.,Take early in the day to prevent insomnia.,May cause weight loss; monitor growth in children.,Avoid alcohol and decongestants (risk of hypertensive crisis).,Report chest pain, palpitations, or shortness of breath immediately.,Do not drive if you feel dizzy or impaired.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METADATE ER vs ADDERALL 10, answered by our medical review team.
METADATE ER is a CNS Stimulant that works by Methylphenidate is a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft. It also acts as a weak agonist at serotonin receptors.. ADDERALL 10 is a CNS Stimulant that works by Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METADATE ER and ADDERALL 10 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METADATE ER is: Initial: 10-20 mg orally once daily in the morning. May increase by 10-20 mg at weekly intervals. Maximum: 60 mg/day.. The standard adult dose of ADDERALL 10 is: 10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METADATE ER and ADDERALL 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METADATE ER is classified as Category C. First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Increased risk of premature delive. ADDERALL 10 is classified as Category C. Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.